NCT02065817已完成不适用
Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- Incorporation of orally administered 13C3 cholesterol into plasma cholesterol
研究概览
简要总结
This is a pilot study to determine the optimum time and dose to draw blood samples using a tracer for HDL kinetics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy men and women ages 18 - 50
排除标准
- •Cardiovascular disease
- •Metabolic disease
- •Hematologic disorder
- •Liver or kidney disease
- •phenylketonuria
- •Currently taking lipid lowering medications or any other drugs that could affect lipid metabolism
结局指标
主要结局
Incorporation of orally administered 13C3 cholesterol into plasma cholesterol
时间窗: 72 hours
13C3 cholesterol, which is labeled with a stable isotope, will be administered orally. Blood samples will be taken every 4-6 hours for 72 hours for the measurement of stable isotopic enrichment in cholesterol using gas chromatography-mass spectrometry. The study has a dual purpose: to determine the optimum oral dose of isotope, and to determine the time of peak enrichment in plasma cholesterol.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of LY3015014 in Participants With High CholesterolHypercholesterolemiaNCT01890967Eli Lilly and Company527
暂停
不适用
Mendelian Reverse Cholesterol Transport StudyCholesterol, HDLLipid Metabolism, Inborn ErrorsTangier DiseaseLCAT DeficiencyCholesteryl Ester Transfer Protein (CETP) DeficiencyNCT01782027University of Pennsylvania30
招募中
不适用
Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology PatientsDrug MonitoringNCT06545292Leiden University Medical Center360
Unknown
1 期
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaGastric CarcinomaNCT00639522Nanjing Sike Pharmaceutical Co., Ltd.18
已完成
不适用
Appropriate Dosing to Optimise Personalised Cancer TreatmentsMelanoma Stage IIIMelanoma Stage IVRenal Cancer Stage IIIRenal Cancer Stage IVLung Cancer, Non-small CellOvarian CancerNCT04154163University of Dundee18